Orforglipron — EU research guide.
Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1 receptor agonist — the first non-peptide small molecule in its class, taken without fasting or water restrictions. It is FDA-approved; not yet reviewed by the EMA.
What is Orforglipron?
Unlike semaglutide or liraglutide, orforglipron is a small molecule rather than a peptide, so it survives the gut without a special absorption enhancer. It activates the GLP-1 receptor to reduce appetite and slow gastric emptying. Eli Lilly's ATTAIN Phase 3 programme supported approval in adults with obesity, or overweight with a weight-related condition.
What does the research show?
In the ATTAIN-1 trial, participants on the highest dose who completed treatment lost an average of 12.4% of body weight versus 0.9% with placebo. The FDA approved Foundayo on 1 April 2026, with a boxed warning for thyroid C-cell tumour risk shared with other GLP-1 medicines.
EU legal status
Not approved in the EU as of mid-2026. Orforglipron is a patented pharmaceutical, not a generic research peptide — and since it isn't even a peptide, it falls outside the scope of most RUO peptide suppliers entirely. Material marketed as “oral orforglipron” by unregulated sellers cannot be verified.
Molecular information
Pharmacokinetics
GLP-1 compounds across EU suppliers
COA-verified EU vendors · Updated monthly